Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06418698
Other study ID # LC2024ZD026
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 28, 2024
Est. completion date June 2029

Study information

Verified date March 2024
Source Zhujiang Hospital
Contact Feng Xin, MD
Phone +8613681134001
Email 13681134001@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.


Description:

This study have to objective to evaluate the predictive value of IAC Agatston score in patients with acute ischemic stroke due to large or medium vessel occlusion on worse angiographic and functional outcomes after EVT. The result of this study will provide a upfront basis for risk stratification of adverse outcomes of EVT by using quantitative IAC, so as to get a reference for an individualized and precise plan of EVT.


Recruitment information / eligibility

Status Recruiting
Enrollment 434
Est. completion date June 2029
Est. primary completion date December 31, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or non-pregnant women with acute stroke symptoms aged over 18 years. - Occlusion of the intracranial internal carotid artery, the middle cerebral artery, the anterior cerebral artery, the posterior cerebral artery, basilar artery and intracranial vertebral artery confirmed by CT, MR angiography, or digital subtraction angiography. - No absolute contraindication to iodinated contrast media. - Planned treatment with EVT by clinical care team. - Informed consent obtained from patients or their legal representatives. - Willing to be followed up as required by the clinical study protocol. Exclusion Criteria: - Acute ischemic stroke occurs over 24 hours of time last known well. - Neurologic deficits caused by diagnoses other than ischemic stroke, such as intracerebral hemorrhage, subarachnoid hemorrhage, or intracranial tumors. - With other underlying factors leading to IAC, such as hyperthyroidism, end-stage renal disease, long-term oral intake of vitamin K antagonist(Warfarin), chronic vitamin D deficiency or overdose, persistent hypomagnesemia, persistent hypercalcemia, persistent hyperphosphatemia and high oral calcium intake. - Lack of non-contract CT images on admission and significant artifacts in CT images preventing IAC measurement. - Severe renal insufficiency (estimated glomerular filtration rate < 30ml/min or serum creatinine > 220µmol/L (2.5mg/dl)). - Previous cerebrovascular intervention treatment or craniotomy.

Study Design


Locations

Country Name City State
China Zhujiang Hospital, Southern Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with a adverse functional outcome at 3 months Modified Rankin Scale(mRS) score > 2 90(±7) days
Secondary Proportion of patients without disability at 3 months mRS score 0-1 90(±7) days
Secondary Proportion of patients with functional independence at 3 months mRS score 0-2 90(±7) days
Secondary Proportion of patients ambulatory or bodily needs-capable or better at 3 months mRS score 0-3 90(±7) days
Secondary Change of the NIHSS score at 24 hours from baseline Change of the NIHSS score at 24 hours from baseline 24 hours
Secondary Change of the NIHSS score at 6 days or discharge if earlier from baseline Change of the NIHSS score at 6 days or discharge if earlier from baseline 6(±1) days
Secondary Health-related quality of life at 3 months Health-related quality of life is assessed with the European Quality Five Dimensions Five Level scale (EQ-5D-5L) 90(±7) days
Secondary Proportion of substantial reperfusion at final angiogram Substantial reperfusion is defined as a expanded Treatment in Cerebral Infarction score of 2b50 (50 to 67% reperfusion), 2b67 (67 to 89% reperfusion), 2c(90 to 99% reperfusion) or 3 (complete reperfusion) 0 day
Secondary Proportion of substantial reperfusion at final angiogram without any rescue methods Substantial reperfusion is defined as a expanded Treatment in Cerebral Infarction score of 2b50 (50 to 67% reperfusion), 2b67 (67 to 89% reperfusion), 2c(90 to 99% reperfusion) or 3 (complete reperfusion) 0 day
Secondary Proportion of substantial reperfusion at first angiogram Substantial reperfusion is defined as a expanded Treatment in Cerebral Infarction score of 2b50 (50 to 67% reperfusion), 2b67 (67 to 89% reperfusion), 2c(90 to 99% reperfusion) or 3 (complete reperfusion) 0 day
Secondary Proportion of patients with Symptomatic intracranial hemorrhage(sICH) within 48 hours ICH will be evaluated according to the Heidelberg Bleeding Classification. sICH is diagnosed if the new observed ICH is associated with any of the following conditions: 1) NIHSS score increased more than 4 points than that immediately before worsening; 2) NIHSS score increased more than 2 points in one category; 3) Deterioration led to intubation, hemicraniectomy, external ventricular drain placement or any other major interventions. Additionally, the symptom deteriorations could not be explained by causes other than the observed ICH. Within 48 hours
Secondary Proportion of patients with any ICH within 48 hours ICH will be evaluated according to the Heidelberg Bleeding Classification. Within 48 hours
Secondary Mortality at 3 months Mortality rates are defined as the number of deaths observed divided by the number of subjects observed over the 90-day study period. 90(±7) days
Secondary Incidence of serious adverse events Including but not limited to acute respiratory failure, severe or malignant cerebral artery infarction, acute heart failure, debridement decompression, and other major medical events that can result in death, immediately life-threatening, hospitalization or prolongation of this hospitalization, terminally or severely disabling/incapacitating, the loss of a significant ability to maintain normal life functioning, or medical intervention to avoid the above outcomes. Within 3 years
Secondary Procedure-related complications such as arterial perforation, iatrogenic arterial dissection, embolization in previously uninvolved vascular territory, arterial access site hematoma, and retroperitoneal hematoma. Arterial perforation will be defined at angiography by the operator and associated with subarachnoid hemorrhage. Iatrogenic arterial dissection will be defined at angiography by the operator. Arterial access site hematoma will be assessed as a complication of arterial access puncture and defined by clinical examination and anatomic imaging. Retroperitoneal hematoma will be assessed as a complication of groin puncture and defined by imaging (ultrasound or CT or MR angiography). The definition of embolization in previously uninvolved vascular territory is noted after recanalization of the primary occlusion site, any vessel occlusions distal from the primary occlusion site are considered emboli due to periprocedural thrombus fragmentation. Up to 24 hours
Secondary Proportion of patients with new cerebrovascular events related with previous vessel occlusion at 1 year New cerebrovascular events are defined as progression of ischemic lesion or newly hemorrhagic lesion. 365(±30) days
Secondary Proportion of patients with new cerebrovascular events related with previous vessel occlusion at 3 years New cerebrovascular events are defined as progression of ischemic lesion or newly hemorrhagic lesion. 1095(±30) days
Secondary Proportion of patients with new cerebrovascular events irrelated with previous vessel occlusion at 1 year New cerebrovascular events are defined as progression of ischemic lesion or newly hemorrhagic lesion. 365(±30) days
Secondary Proportion of patients with new cerebrovascular events irrelated with previous vessel occlusion at 3 years New cerebrovascular events are defined as progression of ischemic lesion or newly hemorrhagic lesion. 1095(±30) days
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05621980 - Finger Movement Training After Stroke N/A